Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2016-A01102-49 | Other Identifier | IDRCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Innate Pharma | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Duration of each part of the study per patient:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Immune cells trafficking | Frequency of T cells in the blood and tissue (Flow cytometry method with a panel of Ab). | Day 0 |
| Measure | Description | Time Frame |
|---|---|---|
| Infiltration of leucocytes in tumor tissue | Histochemical method with a panel of Ab. | Day 0 |
| Safety (Number of adverse events, ECOG status) | After Day 0 until the end of the study (Month 3, Month 6, Month 9, Month 12, Month 15, Month 18,Month 21, Month 24, Month 30, Month 36, Month 42, Month 48, Month 54 and Month 60) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients under guardianship / curatorship
Following Situations
Pregnant or lactating women.
Patients with HIV seropositivity.
Rectal tumor location.
Not provided
Not provided
Not provided
Patient with colon adenocarcinoma treated by surgery
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Matthieu Allez, MD, PhD | Hopital Saint Louis | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Saint Louis | Paris | 75000 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35803702 | Result | Bonnereau J, Courau T, Asesio N, Salfati D, Bouhidel F, Corte H, Hamoudi S, Hammoudi N, Lavole J, Vivier-Chicoteau J, Chardiny V, Maggiori L, Blery M, Remark R, Bonnafous C, Cattan P, Toubert A, Bhat P, Allez M, Aparicio T, Le Bourhis L. Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition. Gut. 2023 Apr;72(4):699-709. doi: 10.1136/gutjnl-2021-326553. Epub 2022 Jul 8. | |
| 30871626 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003110 | Colonic Neoplasms |
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Tissu and blood
| Result |
| Courau T, Bonnereau J, Chicoteau J, Bottois H, Remark R, Assante Miranda L, Toubert A, Blery M, Aparicio T, Allez M, Le Bourhis L. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment. J Immunother Cancer. 2019 Mar 14;7(1):74. doi: 10.1186/s40425-019-0553-9. |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |